Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds new antibiotic effective for diabetic foot infections

16.01.2004


A clinical trial involving 371 patients in eight countries shows that linezolid, a new antibiotic, is at least as effective as two older therapies for treating diabetic foot infections. The drug may be an important new agent for doctors treating infections that are increasingly caused by bacteria resistant to standard antibiotics, and that in severe cases may require amputation. The study, led by a Department of Veterans Affairs (VA) physician and conducted at 30 U.S. and 15 European sites, appears in the current issue of Clinical Infectious Diseases.



Foot infections are among the most serious complications of diabetes, and a leading cause of diabetes-related hospitalizations. The infections typically occur when pathogens--usually gram-positive bacteria--infect foot ulcers. These sores develop because of diabetes-related nerve damage and loss of feeling in the feet. Amputation may be needed when infections fail to respond to therapy. People with diabetes account for about two-thirds of the 134,000 lower-limb amputations performed each year in the United States.

"The complication of diabetes that patients fear most is leg amputation, and infection is often the final pathway that leads to this tragic, if often preventable, outcome," said lead author Benjamin A. Lipsky, director of the General Internal Medicine and Antibiotic Research clinics at the VA Puget Sound Health Care System and professor of medicine at the University of Washington School of Medicine in Seattle.


Linezolid, sold as Zyvox (Pfizer, Inc.), was approved by the Food and Drug Administration (FDA) in 2000 to treat a variety of infections, including some caused by bacteria resistant to the drug methicillin. Methicillin-resistant Staphylococcus aureus (MRSA) has become a major cause of infections--including diabetic foot infections--both in hospitals and communities. For years the antibiotic vancomycin had been a last line of defense against infections caused by MRSA and other antibiotic-resistant "superbugs," but now vancomycin-resistant infections have been reported.

Because of the growing problem of MRSA and vancomycin-resistant enterococci (VRE), new agents have been developed. Linezolid is among the first new treatments for MRSA infections since vancomycin was introduced in the 1950s. Based on the results of the new trial, the FDA has now specifically extended the drug’s use to most diabetic foot infections.

Unlike other newer antibiotics for MRSA and VRE, linezolid can be given orally, as well as intravenously, making it suitable for outpatient use.

"The approval of this drug for appropriately selected diabetic foot infections is important because it may reduce the need to hospitalize patients and the risk of IV-related complications," said Lipsky.

In the study, patients with diabetic foot infections were randomly assigned to receive either linezolid or one of two standard combination treatments, consisting of an aminopenicillin and a betalactamase inhibitor, a drug that blocks an enzyme that inactivates penicillin. Vancomycin could be added to the regimen for patients in the non-linezolid group if their infection was caused by MRSA.

Linezolid produced a clinical cure for 81 percent of patients, while the comparator combination was effective for 71 percent of patients. Statistically, the overall results for the two groups were about equal. However, linezolid outperformed the aminopenicillin treatments in the largest subgroup: patients with an infected ulcer, as opposed to cellulitis, osteomyelitis, or other less common types of diabetic foot infections.

Lipsky’s results were presented in part at the Oct. 2002 annual meeting of the Infectious Diseases Society of America. The study was supported by VA and Pharmacia, now part of Pfizer, the maker of linezolid. Lipsky has served as a consultant and speaker for Pharmacia and Pfizer.


NOTE FOR REPORTERS: Dr. Benjamin A. Lipsky, is the lead author for this study. For interviews, please contact Jeri Rowe or Ellen Flores, of the VA Puget Sound Health Care System, at 206-764-2435 or jeri.rowe@med.va.gov or ellen.flores@med.va.gov.

Jeri Rowe | EurekAlert!

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>